GSA Capital Partners’s Cascadian Therapeutics, Inc. CASC Stock Holding History

GSA Capital Partners’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,950	Closed	-$49K	–	2095
2016 Q3	$49K	Buy	+4,950	New	+$35.1K	﹤0.01%	1727
2015 Q3	–	Sell	-3,367	Closed	-$76K	–	2185
2015 Q2	$76K	Sell	3,367 -5,384	-62%	-$85.2K	﹤0.01%	1882
2015 Q1	$86K	Buy	+8,751	New	+$85.8K	﹤0.01%	2033

Other funds holding CASC

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

GSA Capital Partners's CASC Position: Q4 2016 in Review

GSA Capital Partners sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2016, closing a stake of 4,950 shares — an estimated $49K sold.

GSA Capital Partners first reported a position in CASC in Q1 2015 and held it in 3 quarters. The position peaked at $86K in Q1 2015. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

GSA Capital Partners reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
GSA Capital Partners sold 4,950 Cascadian Therapeutics, Inc. shares in Q4 2016, an estimated $49K.
GSA Capital Partners first reported a position in Cascadian Therapeutics, Inc. in Q1 2015 and held it in 3 quarters.
GSA Capital Partners's Cascadian Therapeutics, Inc. position peaked at $86K in Q1 2015.
57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on GSA Capital Partners's 13F filing for Q4 2016, filed 14 Feb 2017.